Study version 1.3, published on 2022-12-09 To view the full version with graphics, please click here. Introduction We review, in this article, a list of problems in the Pfizer/BioNTech C4591001 Trial, which came out in our attempts to reproduce the results provided by the study. Using the sponsor’s data communicated to […]
“170 Patients That Changed Everything” – Spectator | Australia
Few people realise that the Emergency Use Authorisation (EUA) of the Pfizer-BioNTech Covid-19 Vaccine/BNT162b2 was granted on the efficacy data of 170 patients. The 162 who received a placebo and 8 patients who were vaccinated formed the basis of the 95 per cent efficacy claims. There has not been much […]
Report 19: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Team Five: Review of Polack with comments and questions. “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine“ Fernando P. Polack, M.D., Stephen J. Thomas, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Perez Marc, M.D., Edson D. Moreira, […]
Report 03: Phase 1 /2 Study of COVID-19 RNA Vaccine BNT162b1 in Adults: Key Processes Missing.
Mulligan, Lyke et al. Nature Published online August 12, 2020. Cite this article as: Mulligan, M. J. et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature https://doi.org/10.1038/s41586-020-2639-4 (2020). P1 p2: The authors’ put forth the argument that mRNA in BNT162b1 (Note this series used BNT162b1 […]